The advent of immunotherapy, specifically of immune checkpoint inhibitors (ICIs), for the
treatment of solid tumors has deeply transformed therapeutic algorithms in medical …

Simple Summary Immunotherapy has been introduced as a standard of care for several
cancers, and its use is on the rise. However, the enhanced immune system frequently …

Immune checkpoint inhibitors (ICIs) are approved as the first-line drug for treating many
cancers and has shown significant survival benefits; however, it also causes immune-related …

In recent years, there has been significant research interest in the field of immunotherapy for
non-small cell lung cancer (NSCLC) within the academic community. Given the observed …

Inflammatory disease of the pituitary gland is known as hypophysitis. There are multiple
histological subtypes, the most common being lymphocytic, and the pathogenesis is variable …

ABSTRACT Background/Purpose Vasculitis as an immune-related adverse event (irAE) from
checkpoint inhibitor therapy (ICI) to treat cancer is a rare clinical event, and little is known …

Introduction Health-related quality of life (HRQoL) is emerging as an endpoint, adjunct to
survival, in cancer treatment. For this reason, the European Organization for Research and …

Cancer immunotherapy, particularly immune checkpoint inhibitors, has positively impacted
oncological treatments. Despite its effectiveness, immunotherapy is associated with immune …

BACKGROUND Hepatocellular carcinoma (HCC) is one of the most common cancers
worldwide and has a high mortality. However, the treatment options for advanced HCC are …

Abstract The American Society of Clinical Oncology (ASCO) updated the guidelines for the
treatment of advanced gastroesophageal (GE) cancer in 2023, signifying a major shift …